Molecular Genetics and Metabolism Reports (Jun 2019)

A closer look at ARSA activity in a patient with metachromatic leukodystrophy

  • Kathleen Doherty,
  • S. Barron Frazier,
  • Matthew Clark,
  • Anna Childers,
  • Sumit Pruthi,
  • David A. Wenger,
  • Jessica Duis

Journal volume & issue
Vol. 19

Abstract

Read online

Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease mainly caused by a deficiency of arylsulfatase A activity. The typical clinical course of patients with the late infantile form includes a regression in motor skills with progression to dysphagia, seizures, hypotonia and death. We present a case of a 4-year-old female with rapidly progressive developmental regression with loss of motor milestones, spasticity and dysphagia. MRI showed volume loss and markedly abnormal deep white matter. Enzymatic testing in one laboratory showed arylsulfatase A activity in their normal range. However, extraction of urine showed a large increase in sulfatide excretion in a second laboratory. Measurement of arylsulfatase A in that laboratory showed a partial decrease in arylsulfatase A activity measured under typical conditions (about 37% of the normal mean). When the concentration of substrate in the assay was lowered to one quarter of that normally used, this individual had activity <10% of controls. The patient was found to be homozygous for an unusual missense mutation in the arylsulfatase A gene confirming the diagnosis of MLD. This case illustrates the importance of careful biochemical and molecular testing for MLD if there is suspicion of this diagnosis. Keywords: Metachromatic Leukodystrophy, Leukodystrophy, Arylsulfatase A, Lysosomal storage disease, Inborn error of metabolism